EMBED 3.0 - Improvement of Formulations
- Buyer
- Cardiff University
- Published
- 2026-10-19
- Deadline
- Not provided
- Sources
- UK_FTS
- Value
- Not provided
Description
The description is in the source language.
The B&M Gates Foundation (funder) have reviewed the work with the EMBED research team, undertaken with the manufacturer ProMed, and have decided that to push the EMBED 3.0 project into its next stage (EMBED 4.0 – Human Trials), they’ll need to demonstrate their ability to vary the additional batches offer a more robust mechanism for the medications to enter patients. The additional work has been again funded by the foundation for the purpose of increasing the viability of the delivery method (technology developed as part of EMBED) - Previous direct award for the initial development via Regulation 41 - Schedule 5, para 2.
Membership
Read notice previews free of charge. Official notice and document links, construction permits and personal MCP access require an active paid membership.
Read